FGI Surges 100% as EPS Revisions Spark Rally in 5 Stocks
Five stocks detected by our EPS revision screener delivered outsized gains, with FGI leading at 100.0% after its forward EPS growth estimate was raised to 500.0% on April 13. AESI's EPS forecast jumped 27.0 percentage points (from 138.4% to 165.4%), driving a 31.8% price surge, while REPL saw its growth estimate climb 12.0pp to 46.4%, resulting in a 33.5% gain. The moves suggest investors are responding aggressively to improving profitability forecasts across consumer cyclical, energy, and healthcare sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FGI | Consumer Cyclical | 2026-04-13 | N/A | +100.0% |
| CRDO | Technology | 2026-04-13 | +0.8pp | +41.0% |
| LEGN | Healthcare | 2026-04-14 | +0.4pp | +38.7% |
| REPL | Healthcare | 2026-04-13 | +12.0pp | +33.5% |
| AESI | Energy | 2026-04-13 | +26.9pp | +31.8% |
Why did FGI stock jump in April 2026?
FGI jumped 100.0% (from $3.85 to $7.70) after analysts raised its forward EPS growth estimate to 500.0% on April 13.
The consumer cyclical stock more than doubled in nine days as the screener flagged an extreme bullish revision to next-year earnings. No recent news catalysts were identified, suggesting the move was driven entirely by updated financial expectations. The outsized EPS revision signals a dramatic improvement in projected profitability for the small-cap company.
View screener snapshot from 2026-04-13 →
FAQ: FGI
Why did FGI stock jump 100% on April 13, 2026?
FGI surged 100.0% from $3.85 to $7.70 after analysts raised its forward EPS growth estimate to 500.0%, indicating expectations of a fivefold increase in next-year earnings per share.
Is FGI a buy after the 100% rally?
The 500.0% EPS growth projection is exceptionally high and warrants caution; the stock has already doubled, potentially pricing in much of the anticipated earnings improvement.
What caused FGI's surge in April 2026?
No news catalysts were identified; the 100.0% gain appears driven entirely by the screener-detected EPS estimate revision from analysts covering the consumer cyclical name.
Why did CRDO stock jump in April 2026?
CRDO jumped 41.0% (from $134.36 to $189.49) after analysts raised its forward EPS growth estimate from 42.5% to 43.2% on April 13.
The technology sector name has sustained momentum through mid-April as the screener confirmed upward earnings momentum. Credo Technology operates in the high-speed connectivity space, where AI infrastructure demand continues driving sector-wide valuation upgrades. The modest 0.8 percentage point revision translated into substantial price appreciation, suggesting the market is sensitive to any positive earnings trajectory in tech.
View screener snapshot from 2026-04-13 →
FAQ: CRDO
Why did CRDO stock jump 41% on April 13, 2026?
CRDO climbed 41.0% from $134.36 to $189.49 after analysts raised its forward EPS growth estimate from 42.5% to 43.2%, signaling improved profitability expectations for the technology company.
Is CRDO a buy after the 41% rally?
CRDO has gained 41% and trades at $189.49; the 43.2% EPS growth projection remains attractive for a tech name, but the rally may have discounted near-term upside.
What caused Credo Technology's surge this week?
The 41.0% gain followed a 0.8 percentage point upward revision to next-year EPS estimates, with AI infrastructure demand providing a favorable sector backdrop for the semiconductor-related company.
Why did LEGN stock jump in April 2026?
LEGN jumped 38.7% (from $18.69 to $25.93) after analysts raised its forward EPS growth estimate from 311.9% to 312.3% on April 14.
The biotech stock gained momentum through the healthcare sector as investors rotated into names with strong earnings growth trajectories. Legend Biotech develops CAR-T cell therapies for cancer treatment, a niche with significant commercial potential. Even a marginal 0.4 percentage point revision reinforced the market's confidence in the company's path to profitability, amplifying price appreciation.
View screener snapshot from 2026-04-14 →
FAQ: LEGN
Why did LEGN stock jump 38.7% on April 14, 2026?
LEGN surged 38.7% from $18.69 to $25.93 after analysts raised its forward EPS growth estimate from 311.9% to 312.3%, reflecting continued confidence in the biotech's path to profitability.
Is LEGN a buy after the healthcare rally?
The 312.3% EPS growth projection is substantial, but LEGN has already rallied 38.7%; investors should assess whether commercial catalysts for its CAR-T therapies justify further upside.
What caused Legend Biotech's surge?
Legend Biotech gained 38.7% as the EPS screener detected a positive revision to its 312.3% forward growth estimate, with sector rotation into healthcare names amplifying the move.
Why did REPL stock jump in April 2026?
REPL jumped 33.5% (from $1.70 to $2.27) after analysts raised its forward EPS growth estimate from 34.4% to 46.4% on April 13.
The 12.0 percentage point revision was the most significant among healthcare names detected, signaling substantially improved earnings expectations. Replimune Group develops oncolytic immunotherapies for cancer treatment, a pipeline with high upside potential as clinical programs advance. The combination of a large EPS revision and the company's speculative growth profile attracted momentum traders to the healthcare penny stock.
View screener snapshot from 2026-04-13 →
FAQ: REPL
Why did REPL stock jump 33.5% on April 13, 2026?
REPL climbed 33.5% from $1.70 to $2.27 after analysts raised its forward EPS growth estimate by 12.0 percentage points to 46.4%, the largest revision among detected healthcare names.
Is REPL a buy after the 33% rally?
The 46.4% EPS growth projection represents meaningful upside, but REPL's sub-$3 price and clinical-stage status make it a higher-risk speculative play within the biotech sector.
What caused Replimune Group's surge?
Replimune surged 33.5% as a 12.0 percentage point EPS revision to 46.4% growth signaled materially improved profitability expectations for the oncolytic immunotherapy developer.
Why did AESI stock jump in April 2026?
AESI jumped 31.8% (from $11.71 to $15.43) after analysts raised its forward EPS growth estimate from 138.4% to 165.4% on April 13.
The 27.0 percentage point revision was the largest magnitude jump among all detected stocks, with the energy sector benefiting from sustained commodity price strength. Atlas Energy Solutions operates in the proppant and logistics space serving oil and gas producers, positioning it to benefit from increased drilling activity. The strong EPS revision validated investor optimism around the energy name's earnings trajectory, driving above-market returns.
View screener snapshot from 2026-04-13 →
FAQ: AESI
Why did AESI stock jump 31.8% on April 13, 2026?
AESI climbed 31.8% from $11.71 to $15.43 after analysts raised its forward EPS growth estimate by 27.0 percentage points to 165.4%, the largest magnitude revision among detected stocks.
Is AESI a buy after the energy sector rally?
The 165.4% EPS growth projection is compelling, but the 31.8% price surge may have already priced in near-term upside from the proppant supplier's earnings momentum.
What caused Atlas Energy Solutions' surge?
Atlas Energy Solutions gained 31.8% following a 27.0 percentage point EPS revision to 165.4% growth, as commodity price strength in the energy sector reinforced bullish earnings forecasts.
The five-stock rally demonstrates how EPS estimate revisions, even modest ones, can trigger outsized price moves when market sentiment is aligned with a sector's momentum. Healthcare names showed particular strength this week, while the energy sector's continued momentum suggests commodity tailwinds remain a driving force for valuation expansion.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →